1. Market Research
  2. > Pharmaceutical Market Trends
Salix Pharmaceuticals, Ltd. - Strategy and SWOT Report

Salix Pharmaceuticals, Ltd.: Company & Financial Report

  • February 2016
  • 25 pages
  • ID: 2515310
In this report:
The transaction is expected to be accretive to earnings per share in the first full year post-closing and accretive by ##-##% in 2017 versus Endo's current plan.
Upon completion of the merger, shareholders of Salix are expected to own slightly less than ##% of the ordinary shares of Salix Pharmaceuticals, plc and Cosmo is expected to own slightly more than ##%.

Summary

Table of Contents

Search Inside

Presentation

Salix Pharmaceuticals, Limited - This report is an all-inclusive source of corporate data and information. The study describes the company's organization, performance, strengths, weaknesses, opportunities and threats analysis, as well as products and services, and corporate activities, offering a 360? overview of the company.

Main elements:

- Comprehensive data on Salix Pharmaceuticals, Limited needed to understand the competitive landscape and business

- A study of the main internal and external factors affecting Salix Pharmaceuticals, Limited with the study of the strengths, weaknesses, opportunities and threats

- A detailed panorama of the business model of Salix Pharmaceuticals, Limited such as a classification and an overview of the main segments of the business

- Insights on Salix Pharmaceuticals, Ltd.'s M&A, important business deals, legal and financial advisors, capital raising and investment funds

- News about Salix Pharmaceuticals, Limited, including industry restructuring, expansion and agreements closed

- Large number of easy-to-grip charts and graphs that exhibit crucial information and key forecasts

Key Findings:

Salix Pharmaceuticals is a specialty pharmaceutical company involved in the acquisition, development and commercialization of prescription pharmaceutical products for the treatment of gastrointestinal diseases. The company's marketed drugs contain Xifaxan, Osmoprep and Metozolv ODT. Salix mainly operates in the USA, where it is based in Raleigh, North Carolina. It employed about 1,000 people as of December 31, 2014. The company reported incomes of $1133.50M during the financial year ended December 2014 (FY2014), a rise of 24.0 percent over FY2013. The operating loss of the company was $490.10M in FY2014, as distinguished to an operating profit of $252.30M in FY2013. The net loss of the company was $414.90M in FY2014, as distinguished to a net profit of $130.80M in FY2013.

Reasons to acquire:

- Gain understanding of Salix Pharmaceuticals, Limited and the elements impacting the strategy of the company

- Track tactical initiatives of the company and recent business news and actions

- Assess Salix Pharmaceuticals, Limited as a potential competitor or partner

- Support sales activities by understanding your clients' businesses superior

- Stay up to date on Salix Pharmaceuticals, Ltd.'s corporate and business organization, action plans and perspectives

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline Review, H2 2018

Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline Review, H2 2018

  • $ 2000
  • September 2018

Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Leber’s Hereditary Optic ...

Zika Virus Infections Global Clinical Trials Review, H2, 2018

Zika Virus Infections Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Zika Virus Infections Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Zika Virus Infections Global Clinical Trials Review, H2, 2018" provides an overview of Zika ...

Clinical Research in Tropical Spastic Paraparesis in H2, 2018

Clinical Research in Tropical Spastic Paraparesis in H2, 2018

  • $ 2500
  • September 2018

Tropical Spastic Paraparesis Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Tropical Spastic Paraparesis Global Clinical Trials Review, H2, 2018" provides an overview ...

Rabies - Pipeline Review, H2 2018 $ 2000 October 2018


ref:plp2016

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on